579 related articles for article (PubMed ID: 14648380)
1. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
[TBL] [Abstract][Full Text] [Related]
2. Patient-derived dendritic cells transduced with an a-fetoprotein-encoding adenovirus and co-cultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against hepatocellular carcinoma cells.
González-Carmona MA; Märten A; Hoffmann P; Schneider C; Sievers E; Schmidt-Wolf IG; Sauerbruch T; Caselmann WH
Liver Int; 2006 Apr; 26(3):369-79. PubMed ID: 16584401
[TBL] [Abstract][Full Text] [Related]
3. [Immunotherapy: new insights].
Geissler M; Weth R
Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
[TBL] [Abstract][Full Text] [Related]
4. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
5. Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma.
Ritter M; Ali MY; Grimm CF; Weth R; Mohr L; Bocher WO; Endrulat K; Wedemeyer H; Blum HE; Geissler M
J Hepatol; 2004 Dec; 41(6):999-1007. PubMed ID: 15582134
[TBL] [Abstract][Full Text] [Related]
6. Potential of immunotherapy for hepatocellular carcinoma.
Breous E; Thimme R
J Hepatol; 2011 Apr; 54(4):830-4. PubMed ID: 21145836
[TBL] [Abstract][Full Text] [Related]
7. Is there a role for immunotherapy in hepatocellular carcinoma?
Zerbini A; Pilli M; Ferrari C; Missale G
Dig Liver Dis; 2006 Apr; 38(4):221-5. PubMed ID: 16461021
[TBL] [Abstract][Full Text] [Related]
8. alpha-fetoprotein and interleukin-18 gene-modified dendritic cells effectively stimulate specific type-1 CD4- and CD8-mediated T-Cell response from hepatocellular carcinoma patients in Vitro.
Cao DY; Yang JY; Dou KF; Ma LY; Teng ZH
Hum Immunol; 2007 May; 68(5):334-41. PubMed ID: 17462500
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of hepatocellular carcinoma.
Korangy F; Höchst B; Manns MP; Greten TF
Expert Rev Gastroenterol Hepatol; 2010 Jun; 4(3):345-53. PubMed ID: 20528121
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
Kong J; Diao Z; Deng X; Zhong H; Yao W; Hu X
Oncol Rep; 2007 Jul; 18(1):279-85. PubMed ID: 17549380
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.
Sun K; Wang L; Zhang Y
Cell Mol Immunol; 2006 Jun; 3(3):197-203. PubMed ID: 16893500
[TBL] [Abstract][Full Text] [Related]
12. Advances in specific immunotherapy for prostate cancer.
Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
[TBL] [Abstract][Full Text] [Related]
13. Activation of dendritic cells by local ablation of hepatocellular carcinoma.
Ali MY; Grimm CF; Ritter M; Mohr L; Allgaier HP; Weth R; Bocher WO; Endrulat K; Blum HE; Geissler M
J Hepatol; 2005 Nov; 43(5):817-22. PubMed ID: 16087270
[TBL] [Abstract][Full Text] [Related]
14. Adaptive immunity in hepatocellular carcinoma: prognostic and therapeutic implications.
Fatourou EM; Koskinas JS
Expert Rev Anticancer Ther; 2009 Oct; 9(10):1499-510. PubMed ID: 19828011
[TBL] [Abstract][Full Text] [Related]
15. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma.
Vollmer CM; Eilber FC; Butterfield LH; Ribas A; Dissette VB; Koh A; Montejo LD; Lee MC; Andrews KJ; McBride WH; Glaspy JA; Economou JS
Cancer Res; 1999 Jul; 59(13):3064-7. PubMed ID: 10397245
[TBL] [Abstract][Full Text] [Related]
16. Strategies for successful vaccination against hepatocellular carcinoma.
Rinaldi M; Iurescia S; Fioretti D; Ponzetto A; Carloni G
Int J Immunopathol Pharmacol; 2009; 22(2):269-77. PubMed ID: 19505380
[TBL] [Abstract][Full Text] [Related]
17. Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma.
Korangy F; Ormandy LA; Bleck JS; Klempnauer J; Wilkens L; Manns MP; Greten TF
Clin Cancer Res; 2004 Jul; 10(13):4332-41. PubMed ID: 15240519
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of DC fused with allogeneic hepatocellular carcinoma cell line HepG2 and autologous tumor cells as potential cancer vaccines against hepatocellular carcinoma.
Cao DY; Yang JY; Yue SQ; Tao KS; Song ZS; Wang DS; Yang YL; Dou KF
Cell Immunol; 2009; 259(1):13-20. PubMed ID: 19545862
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.
Si S; Sun Y; Li Z; Ge W; Zhang X; Hu P; Huang Y; Chen G; Song H; Huang Y; Ma B; Li X; Sui Y
Gene Ther; 2006 Nov; 13(22):1603-10. PubMed ID: 16855617
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma.
Ren J; Jia J; Zhang H; Zhang L; Ma B; Jiang H; Di L; Song G; Yu J
Cancer Sci; 2008 Jul; 99(7):1420-6. PubMed ID: 18422751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
